Current Value
$1.931 Year Return
Current Value
$1.931 Year Return
Yahoo
Multi-centre trial evaluating efti in combination with pembrolizumab and chemotherapy in patients with non-small cell lung cancer reaches enrolment target of approximately 50 evaluable patientsData updates from INSIGHT-003 are expected in 2025 and beyond SYDNEY, AUSTRALIA, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today an
Yahoo
Favourable safety profile for world’s first LAG-3 agonist, IMP761, with no treatment related adverse events to dateAdditional safety data and assessment of PK/PD relationships to follow in first half of CY2025IMP761 is designed to enhance the “brake” function of LAG-3 on T cells to restore balance to the immune system and address the underlying cause of many autoimmune diseases SYDNEY, AUSTRALIA, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Compan
Yahoo
Findings published in Science Immunology resolve how human LAG-3 binds to its main ligand providing a better foundation for development of blocking LAG-3 therapeutics, including Immutep’s anti-LAG-3 small molecule programData also supports eftilagimod alfa’s (efti) preferential binding to a subset of MHC Class II molecules on antigen-presenting cells leading to their activation SYDNEY, AUSTRALIA, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Compan
Yahoo
Immutep (IMMP) announces positive clinical results from Cohort B of the TACTI-003 Phase IIb trial. This study evaluates eftilagimod alpha in combination with MSD’s anti-PD-1 therapy KEYTRUDA in first line recurrent/metastatic head and neck squamous cell carcinoma patients with negative PD-L1 expression. Data as of the 31 October 2024 cut-off date in evaluable 1L HNSCC patients whose tumours express PD-L1 below 1 and who typically do not respond well to anti-PD-1 therapy alone shows: Positively,
Yahoo
Data shows strong overall survival, progression-free survival, and durability from novel combination of efti in combination with pembrolizumab in difficult-to-treat head and neck cancer patients with PD-L1 CPS <1Positively, median overall survival (OS) has not yet been reached and the 12-month OS rate is 67%, both well above historical controlsComplete response rate increases to 12.9% and 16.1%, according to RECIST 1.1 and iRECIST, respectivelyTreatment continues to be well tolerated SYDNEY, AUS
Yahoo
Media Release SYDNEY, AUSTRALIA, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces the initiation of the pivotal TACTI-004 Phase III clinical trial for the treatment of first-line metastatic non-small cell lung cancer (1L NSCLC). “The receipt of regulatory approval from the Australian Therapeutic Goods Administrati
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
ELAN | 36.79% | $5.94B | -17.67% | 0.00% |
LEVI | 34.45% | $6.89B | +11.35% | 2.88% |
CODX | 27.05% | $25.38M | -34.84% | 0.00% |
CIG.C | 25.55% | $2.25B | +6.01% | 0.00% |
AVAV | 25.14% | $4.76B | +37.23% | 0.00% |
BAP | 23.40% | $14.49B | +24.31% | 5.06% |
RXRX | 23.15% | $2.55B | -32.19% | 0.00% |
TGT | 21.66% | $61.22B | -3.28% | 3.30% |
LCID | 21.20% | $9.25B | +13.28% | 0.00% |
VSTM | 21.01% | $237.22M | -52.28% | 0.00% |
POOL | 20.97% | $13.33B | -9.46% | 1.33% |
WBA | 20.39% | $10.82B | -43.09% | 8.64% |
AVAL | 20.08% | $847.89M | -15.41% | 5.98% |
DINO | 20.03% | $6.84B | -30.81% | 5.50% |
FSP | 19.89% | $192.63M | -25.30% | 2.12% |
ICL | 19.83% | $7.63B | +31.04% | 3.25% |
PLAB | 19.78% | $1.56B | -21.02% | 0.00% |
TM | 19.71% | $237.72B | -9.91% | 2.96% |
NMAI | 19.62% | - | - | 13.50% |
SM | 19.53% | $4.94B | +21.10% | 1.72% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
LNN | -19.30% | $1.45B | +2.64% | 1.05% |
FIZZ | -18.85% | $3.98B | -3.11% | 0.00% |
ATEX | -17.22% | $576.98M | +4.63% | 0.00% |
GAN | -11.59% | $84.30M | +20.92% | 0.00% |
AJG | -11.45% | $73.65B | +23.46% | 0.81% |
SUZ | -11.32% | $12.78B | +1.30% | 0.00% |
SAVA | -11.25% | $132.30M | -89.58% | 0.00% |
GWRE | -10.85% | $14.91B | +54.95% | 0.00% |
VRSK | -10.78% | $39.33B | +16.00% | 0.56% |
NARI | -9.87% | $4.66B | +38.37% | 0.00% |
MEDP | -9.82% | $10.49B | +14.09% | 0.00% |
NHTC | -9.74% | $55.15M | -22.11% | 16.63% |
TMUS | -9.72% | $254.11B | +32.58% | 1.30% |
OPRX | -9.66% | $88.51M | -67.88% | 0.00% |
HUSA | -9.42% | $21.85M | +7.05% | 0.00% |
BLCO | -9.42% | $6.11B | +18.99% | 0.00% |
IIIV | -9.41% | $555.82M | +21.22% | 0.00% |
LH | -9.23% | $19.95B | +5.49% | 1.20% |
SWBI | -9.16% | $454.55M | -21.33% | 4.91% |
VRNT | -9.09% | $1.52B | -14.10% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
BAND | 0.01% | $431.36M | +15.29% | 0.00% |
RVP | 0.02% | $23.58M | -35.97% | 0.00% |
FOUR | -0.03% | $8.03B | +51.89% | 0.00% |
SOFI | 0.03% | $17.90B | +120.29% | 0.00% |
GH | 0.04% | $4.53B | +57.95% | 0.00% |
FIVN | -0.05% | $2.81B | -51.57% | 0.00% |
FTI | 0.06% | $13.86B | +68.15% | 0.60% |
ACM | 0.06% | $14.45B | +23.08% | 0.83% |
TEF | 0.06% | $22.72B | -2.42% | 7.93% |
ATNI | 0.06% | $231.55M | -57.53% | 6.13% |
RNA | -0.07% | $3.45B | +184.65% | 0.00% |
TPVG | 0.07% | $272.08M | - | 18.35% |
CLFD | 0.07% | $548.25M | +51.54% | 0.00% |
FWONK | -0.08% | $22.68B | +44.67% | 0.00% |
LAC | 0.08% | $762.14M | -23.13% | 0.00% |
WTW | -0.08% | $32.30B | +27.87% | 1.10% |
AFL | 0.09% | $59.16B | +26.22% | 1.88% |
NMIH | 0.09% | $2.98B | +25.48% | 0.00% |
EIG | 0.09% | $1.23B | +21.67% | 2.36% |
UONEK | 0.10% | $44.31M | -73.94% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
FBY | -0.16% | $168.27M | 0.99% |
DUSB | 0.16% | $944.69M | 0.15% |
PDBC | -0.19% | $4.49B | 0.59% |
XHLF | -0.20% | $945.68M | 0.03% |
BILZ | -0.35% | $633.27M | 0.14% |
BSJP | 0.38% | $1.01B | 0.42% |
JBBB | 0.44% | $1.68B | 0.49% |
HACK | 0.50% | $1.96B | 0.6% |
DBA | -0.56% | $807.60M | 0.93% |
BUXX | -0.66% | $197.72M | 0.25% |
CMF | -0.85% | $3.77B | 0.08% |
YOLO | 0.92% | $29.73M | 1.03% |
TBIL | -0.98% | $4.84B | 0.15% |
IAK | 1.00% | $745.59M | 0.39% |
AMDY | 1.03% | $165.49M | 0.99% |
BCI | 1.07% | $1.38B | 0.26% |
DBC | -1.08% | $1.38B | 0.87% |
CGMU | 1.13% | $2.74B | 0.27% |
HYMU | 1.14% | $267.68M | 0.35% |
COMT | -1.17% | $722.55M | 0.48% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VIXY | -19.90% | $195.31M | 0.85% |
HIGH | -13.38% | $245.77M | 0.52% |
EQLS | -12.69% | $9.14M | 1% |
PHDG | -11.56% | $114.88M | 0.39% |
TAIL | -11.44% | $65.49M | 0.59% |
MNA | -11.27% | $215.63M | 0.77% |
TBLL | -10.54% | $1.99B | 0.08% |
USDU | -8.25% | $397.27M | 0.5% |
AGZD | -7.39% | $148.39M | 0.23% |
CANE | -6.83% | $12.21M | 0.29% |
WEAT | -5.66% | $120.18M | 0.28% |
KCCA | -4.95% | $107.36M | 0.87% |
PWZ | -4.29% | $705.34M | 0.28% |
CTA | -3.72% | $555.39M | 0.76% |
UUP | -3.46% | $642.45M | 0.77% |
SHYD | -3.24% | $311.62M | 0.35% |
DBO | -3.11% | $219.60M | 0.77% |
DBE | -2.87% | $51.45M | 0.77% |
GBIL | -2.23% | $5.81B | 0.12% |
EPHE | -1.85% | $91.90M | 0.59% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
EFAA | 34.97% | $104.39M | 0% |
QQA | 24.66% | $147.14M | 0% |
RSPA | 22.74% | $274.39M | 0% |
THTA | 21.70% | $36.93M | 0.49% |
INTF | 20.94% | $1.23B | 0.16% |
GWX | 20.26% | $619.54M | 0.4% |
DBEU | 20.24% | $579.18M | 0.45% |
QAI | 20.17% | $693.42M | 0.91% |
DBEF | 20.01% | $6.99B | 0.35% |
FLGB | 19.82% | $658.75M | 0.09% |
LVHI | 19.79% | $1.57B | 0.4% |
PXF | 19.76% | $1.71B | 0.45% |
FLTR | 19.75% | $1.98B | 0.14% |
ILF | 19.69% | $1.09B | 0.48% |
PID | 19.62% | $816.12M | 0.53% |
HEFA | 19.44% | $5.65B | 0.35% |
EWU | 19.39% | $2.99B | 0.5% |
ESPO | 19.21% | $279.50M | 0.56% |
SCHF | 18.94% | $40.52B | 0.06% |
EFA | 18.89% | $53.76B | 0.32% |